ANKUR DRUGS AND PHARMA LIMITED

Registered Office: C-306, Crystal Plaza, Andheri Link Road, Andheri (West), Mumbai- 400 053

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 3OTH JUNE, 2012

(INR in Lacs)

Sr. No.	Particulars	3 months ended on 30.06.2012 (Un-audited)	Preceeding 3 months ended on 31.03.2012 (Un-audited)	Corresponding 3 months ended on 30.06.2011 (Un-audited)	Year ended on 31.03.2012 (Un-audited)	Previous year ended 31.03.2011 (Audited)
1.	a) Income from Operations (Net of Excise Duty)					
	-Net Sales	2,833.34	3,355.43	4,122.07	14,137.01	82,399.74
	-Job Charges	484.29	422.40	189.16	1,133.25	-
	b) Other Operating Income	9.40	15.90	7.00	37.89	55.93
	Total Income from Operations (Net)	**3,327.03**	**3,793.73**	**4,318.23**	**15,308.15**	**82,455.67**
2.	**EXPENSES**					
	a) Cost of materials consumed/sold	2,162.35	3,037.46	2,125.56	9,357.78	57,679.92
	b) Purchases of stock in trade	-	-	35.23	35.23	-
	c) Changes in inventories of finished goods, work in progress and stock in trade	134.89	137.36	742.07	1,868.45	3,961.96
	d) Employee/Labour benefit expenses	578.12	653.68	760.28	2,891.07	2,865.41
	e) Depreciation and amortisation expenses	1,660.76	1,660.62	1,539.31	6,603.10	6,079.70
	f) Other expenses	740.63	1,110.37	1,148.08	3,966.20	4,643.52
	Total Expenses	5,276.75	6,599.49	6,350.53	24,721.83	**75,230.51**
3.	**PROFIT/(LOSS) FROM OPERATIONS BEFORE OTHER INCOME, INTEREST AND EXCEPTIONAL ITEMS (1-2)**	**(1,949.72)**	**(2,805.76)**	**(2,032.30)**	**(9,413.68)**	**7,225.16**
4.	Other Income	1.69	1.18	-	6.61	122.33
5.	**PROFIT/(LOSS) FROM ORDINARY ACTIVIES BEFORE FINANCE COST AND EXCEPTIONAL ITEMS (3+4)**	**(1,948.03)**	**(2,804.58)**	**(2,032.30)**	**(9,407.07)**	**7,347.49**
6.	**FINANCE COST**					
	a) Interest and other financial charges (net of reversal of interest for previous year)	2,457.36	1,489.43	1,227.68	4,540.58	10,926.97
	b) Provision for exchange difference on FCCBs	1,451.44	1,613.97	-	1,613.97	-
	c) Provision for premium on redemption of FCCBs	492.41	582.79	194.54	1,131.65	1,097.07
7.	**PROFIT/(LOSS) FROM ORDINARY ACTIVITIES AFTER FINANCE COSTS BUT BEFORE EXEPTIONAL ITEMS (5-6)**	**(6,349.24)**	**(6,490.77)**	**(3,454.52)**	**(16,693.27)**	**(4,676.55)**
8.	**EXCEPTIONAL ITEMS**					
	a) Expired Inventories/Goods written off	-	2,336.89	-	2,336.89	-
9.	**PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX (7+8)**	**(6,349.24)**	**(8,827.66)**	**(3,454.52)**	**(19,030.16)**	**(4,676.55)**
10.	**TAX EXPENSE**					
	a) Income Tax (including for earlier years)	-	278.99	-	278.99	141.07
	b) Deferred Tax	-	2,848.25	-	2,848.25	2,063.18
11.	**NET PROFIT/LOSS FROM ORDINARY ACTIVITIES AFTER TAX (9-10)**	**(6,349.24)**	**(11,954.90)**	**(3,454.52)**	**(22,157.40)**	**(6,880.80)**
12	Paid-up Equity Share Capital (of Rs.10/- each)	**1,934.16**	**1,934.16**	**1,934.16**	**1,934.16**	**1,934.16**
13	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	**-**	-	**26,913.23**
14	**Earning per share (Rs.)** (on face value of Rs.10/- each)- (not annualised):					
	-Basic	**(32.83)**	**(61.81)**	**(17.86)**	**(114.56)**	**(35.58)**
	-Diluted	**(11.44)**	**(21.55)**	**(6.23)**	**(39.94)**	**(12.40)**

PART II

A	**PARTICULARS OF SHAREHOLDING**					
1	Public Shareholding					
	-Number of Shares	17,040,009	16,120,865	15,054,709	16,120,865	14,601,709
	-Percentage of Shareholding (%)	88.10	83.35	77.84	83.35	75.49
2	**Promoters and promoter group shareholding****					
	a) Pledged/Encumbered					
	-Number of Shares	1,332,000	2,252,000	3,291,200	2,252,000	3773000
	-Percentage of shares (as a % of the total shareholding of promoter and promoter group)	57.87	69.92	76.77	69.92	79.60
	-Percentage of shares (as a % of the total share capital of the Company)	6.89	11.64	17.02	11.64	19.51
	b) Non-encumbered					
	-Number of Shares	969,581	968,725	995,681	968,725	966881
	-Percentage of shares (as a % of the total shareholding of promoter and promoter group)	42.13	30.08	23.23	30.08	20.40
	-Percentage of shares (as a % of the total share capital of the company)	5.01	5.01	5.14	5.01	5.00

	Particulars	**3 months ended 30/06/2012**
B	**INVESTOR COMPLAINTS**	
	Pending at the beginning of the quarter	0
	Received during the quarter	1
	Disposed of during the quarter	1
	Remaining unresolved at the end of the quarter	NIL

NOTES:

1. The above results were reviewed by the Audit Committee and approved by the Board of Directors of the company in their meeting held on 14th August, 2012
2. The Board appointed Mr. A. K. Khadke, General Manager of Central Bank of India on the Board of the Company as a Nominee Director of Central Bank of India.
3. The Company declared results of Postal Ballot on 6th July, 2012 with regard to the resolutions for Increase in the Authorized Share Capital of the Company, Alteration in the Articles of Association of the Company, Implementation of CDR Scheme and Issue of Equity Shares on a preferential basis to promoters, their Relatives and Associates; which have been passed with the unanimous majority, as per the provisions of the Section 192A of the Companies Act, 1956 read with Companies (Passing of Resolutions by Postal Ballot) Rules, 2011.
4. As the company operates in a single business segment viz: "Pharmaceuticals Formulations", in the context of Accounting Standard 17 disclosure of segment information is not applicable

For **ANKUR DRUGS AND PHARMA LIMITED**

ANKUR DRUGS AND PHARMA LTD. MUMBAI

GIRRAJ VIJAYVARGIYA
Wholetime Executive Director

Place : Mumbai.
Dated: 14th August, 2012